伊匹木单抗-话题@MedSci

#伊匹木单抗#

23篇内容 | 3623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2036785, encodeId=35a72036e8519, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗, objectType=article, longId=180256, objectId=d2b81802562b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2b81802562b, replyNumber=0, likeNumber=92, createdTime=2019-10-26, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2b81802562b, moduleTitle=BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2b81802562b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036786, encodeId=40da2036e868c, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=151, createdTime=2020-06-19, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036781, encodeId=1a4b2036e81a3, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, objectType=article, longId=158125, objectId=cd04158125a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd04158125a7, replyNumber=0, likeNumber=94, createdTime=2019-05-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd04158125a7, moduleTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd04158125a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036784, encodeId=01f72036e84b3, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%, objectType=article, longId=167691, objectId=56da16e69151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56da16e69151, replyNumber=0, likeNumber=221, createdTime=2020-02-23, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56da16e69151, moduleTitle=ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56da16e69151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036782, encodeId=068e2036e8291, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准, objectType=article, longId=158137, objectId=4a7415813e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7415813e30, replyNumber=0, likeNumber=228, createdTime=2019-06-30, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7415813e30, moduleTitle=纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7415813e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036783, encodeId=65d62036e8360, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, objectType=article, longId=167618, objectId=e3fc16e61813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fc16e61813, replyNumber=0, likeNumber=226, createdTime=2019-12-23, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fc16e61813, moduleTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3fc16e61813)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊匹木单抗

2020-05-29

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗

2019-10-26

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2020-06-19

仁者大医 (审核中...)

前往app查看评论内容

#伊匹木单抗#

喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准

2019-05-27

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%

2020-02-23

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准

2019-06-30

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果

2019-12-23

科室
- - 订阅+
  - 更多科室
工具
服务